Intraoperative parathyroid hormone (ioPTH) measurement is widely used to confirm the successful gland excision during parathyroidectomy. However, ioPTH measurement is costly and its use may contribute to increased operating theatre time. This study aimed to determine whether the use of ioPTH is justified for all routine cases.
Intraoperative parathyroid hormone (ioPTH) measurement is widely used to confirm the successful gland excision during parathyroidectomy. However, ioPTH measurement is costly and its use may contribute to increased operating theatre time. This study aimed to determine whether the use of ioPTH is justified for all routine cases.
A total of 211 patients undergoing parathyroidectomies for PHPT for were recruited from McGill University Thyroid Cancer Centre between January 2007 and December 2012. Patients were imaged by ultrasound and Technetium ( 99m Tc) sestamibi scan prior to surgery with non-concordant results confirmed by magnetic resonance imaging. Serum PTH was measured prior to the initiation of surgery and at 12 min post-gland excision using a Cobas 8000 analyser. A decrease in ioPTH to less than 50% of the pre-excision level indicated successful removal of the hyperactive gland. On excision, the suspected adenoma was also sent for frozen section analysis.
ioPTH measurement led to a change in management in only four of 211 (2%) patients. Patients in whom an adenoma was localised preoperatively by two concordant imaging results (186 of 211 patients) benefited less from ioPTH compared to patients whose imaging did not confirm adenoma localisation. ioPTH was considered useful in two of 186 (1.08%) patients with preoperative localisation and two of 25 patients (8%) without adequate preoperative localisation (P ¼ 0.017).
These results raise questions regarding the clinical utility of ioPTH measurement in patients where preoperative localisation of the hyperactive gland has been confirmed by two modalities of investigation. Romosozumab is a humanised monoclonal antibody to sclerostin, an osteocyte-derived glycoprotein that inhibits osteoblast proliferation and function, and thus decreases bone formation. This article presents the results of an industry-sponsored phase 2, multicentre, randomised, placebo-controlled trial that compared increasing doses of subcutaneous romosozumab with two comparator drugs -oral alendronate (70 mg weekly) and subcutaneous teriparatide (20 mg daily), as well as placebo in healthy postmenopausal women with osteopenia. The primary endpoint was change in bone mineral density (BMD) at the lumbar spine at 12 months. Secondary endpoints included changes in BMD at other sites, and markers of bone turnover (serum P1NP, osteocalcin and BALP (formation), and -CTX (resorption)).
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All dose levels of romosozumab were associated with striking increases in BMD at all sites except the distal radius (no change). Indeed, at the highest dose of 210 mg per month, BMD at the spine increased by 11.3% compared to 4.1% with alendronate and 7.1% with teriparatide. Changes in bone markers differ from existing osteoporosis therapies. Formation markers rose rapidly after the initial dose, but then declined to baseline or below, whereas -CTX dropped initially and remained below baseline at 12 months in those receiving monthly doses of the drug.
Limitations include small study groups, short trial duration and a non-diseased study population. A phase 3 clinical trial is currently underway in postmenopausal osteoporotic women which will hopefully address whether BMD increases translate into reduced fracture rates. 
